AstraZeneca AB v Apotex Pty Ltd

HIGH COURT OF AUSTRALIAFRENCH CJ,KIEFEL, GAGELER, KEANE AND NETTLE JJMatter No S54/2015ASTRAZENECA AB & ANOR  APPELLANTSANDAPOTEX PTY LTD  RESPONDENTMatter No S55/2015ASTRAZENECA AB & ANOR  APPELLANTSANDWATSON PHARMA PTY LTD   RESPONDENTMatter No S56/2015ASTRAZENECA AB & ANOR  APPELLANTSANDASCENT PHARMA PTY LTD  RESPONDENTAstraZeneca AB v Apotex Pty LtdAstraZeneca AB v Watson Pharma Pty LtdAstraZeneca AB v Ascent Pharma Pty Ltd[2015] HCA 302 September 2015S54/2015, S55/2015 & S56/2015ORDERIn each matter, appeal dismissed with costs.On appeal from the Federal Court of AustraliaRepresentationA J L Bannon SC with C Dimitriadis SC and C J Burgess for the appellants in each matter (instructed by Ashurst Australia)D K Catterns QC with N R Murray for the respondent in S54/2015 (instructed by Herbert Smith Freehills)A J Ryan SC with I P Horak for the respondents in S55/2015 and S56/2015 (instructed by Minter Ellison Lawyers)J T Gleeson SC, Solicitor-General of the Commonwealth with F T Roughley for the Commonwealth of Australia, intervening (instructed by Corrs Chambers Westgarth)Notice:  This copy of the Court's Reasons for Judgment is subject to formal revision prior to publication in the Commonwealth Law Reports.CATCHWORDSAstraZeneca AB v Apotex Pty LtdAstraZeneca AB v Watson Pharma Pty LtdAstraZeneca AB v Ascent Pharma Pty LtdIntellectual property – Patents – Patents Act 1990 (Cth) – Inventive step – Obviousness – Patent disclosing method of treatment for hypercholesterolemia – Administration of rosuvastatin and its pharmaceutically acceptable salts at low dosage range in claims – Whether invention obvious in light of common general knowledge together with two prior art documents considered separately where another...